Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Apatinib + Chemo for Neoadjuvant Biliary Tract Cancer
NCT06181032Phase 1Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Dec 2023
- Primary completion
- Feb 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adebrelimab in biliary tract cancer (BTC), sponsored by The First Hospital of Fujian Medical University. Primary endpoints: Relapse Free Survival at 3 years and Adverse Events at 3 years. Started Dec 2023; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06181032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06181032.